• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    12/6/23 8:06:55 AM ET
    $ALLR
    $BCLI
    $BIOL
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • Phio Pharma (NASDAQ:PHIO) stock increased by 33.9% to $1.5 during Wednesday's pre-market session. The company's market cap stands at $3.6 million.
    • Tenax Therapeutics (NASDAQ:TENX) shares moved upwards by 18.41% to $0.4. The market value of their outstanding shares is at $9.4 million.
    • Brainstorm Cell (NASDAQ:BCLI) stock rose 18.0% to $0.36. The market value of their outstanding shares is at $17.6 million.
    • Altamira Therapeutics (NASDAQ:CYTO) stock rose 17.45% to $0.43. The market value of their outstanding shares is at $3.3 million.
    • Rani Therapeutics Hldgs (NASDAQ:RANI) shares moved upwards by 15.41% to $2.62. The company's market cap stands at $67.8 million.
    • Minerva Surgical (NASDAQ:UTRS) shares increased by 14.4% to $2.78. The company's market cap stands at $24.6 million.

    Losers

    • OptiNose (NASDAQ:OPTN) stock declined by 16.3% to $1.23 during Wednesday's pre-market session. The market value of their outstanding shares is at $138.1 million.
    • Allarity Therapeutics (NASDAQ:ALLR) shares declined by 12.19% to $0.51. The company's market cap stands at $2.4 million.
    • Biolase (NASDAQ:BIOL) shares decreased by 9.31% to $1.17. The company's market cap stands at $1.2 million.
    • Conduit Pharmaceuticals (NASDAQ:CDT) shares fell 8.96% to $2.44. The market value of their outstanding shares is at $180.1 million.
    • Evelo Biosciences (NASDAQ:EVLO) stock declined by 8.89% to $0.35. The market value of their outstanding shares is at $6.6 million.
    • Lucy Scientific Discovery (NASDAQ:LSDI) stock fell 7.87% to $0.28. The company's market cap stands at $4.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $BCLI
    $BIOL
    $CDT

    CompanyDatePrice TargetRatingAnalyst
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    OptiNose Inc.
    $OPTN
    3/20/2025Buy → Hold
    Lake Street
    OptiNose Inc.
    $OPTN
    1/3/2025$5.00 → $18.00Buy
    H.C. Wainwright
    Tenax Therapeutics Inc.
    $TENX
    10/24/2024$16.00Outperform
    Leerink Partners
    Tenax Therapeutics Inc.
    $TENX
    10/14/2024$16.00Buy
    Guggenheim
    Tenax Therapeutics Inc.
    $TENX
    9/30/2024Outperform
    William Blair
    More analyst ratings

    $ALLR
    $BCLI
    $BIOL
    $CDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BCLI
    $BIOL
    $CDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Farley Chele Chiavacci was granted 10,553 shares, increasing direct ownership by 160% to 17,157 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    2/23/26 8:27:01 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lockshin Curtis was granted 16,600 shares, increasing direct ownership by 89% to 35,155 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    2/6/26 8:01:09 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Freeman Jonathan E was granted 16,600 shares, increasing direct ownership by 103% to 32,655 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    2/6/26 8:00:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BCLI
    $BIOL
    $CDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT

    The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com KING OF PRUSSIA, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th, 2026. Mr. Bitterman

    3/10/26 7:59:39 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

    The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.comKing of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th, 2026. Mr. Bit

    3/10/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BCLI
    $BIOL
    $CDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Tenax Therapeutics with a new price target

    Piper Sandler initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $20.00

    9/8/25 8:59:21 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendiant Capital Markets initiated coverage on Allarity Therapeutics with a new price target

    Ascendiant Capital Markets initiated coverage of Allarity Therapeutics with a rating of Buy and set a new price target of $9.00

    7/28/25 8:53:33 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Phio Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00

    6/5/25 7:35:43 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BCLI
    $BIOL
    $CDT
    SEC Filings

    View All

    SEC Form 10-K filed by Tenax Therapeutics Inc.

    10-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    3/10/26 7:48:55 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    3/10/26 7:32:44 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - CDT Equity Inc. (0001896212) (Filer)

    3/9/26 4:05:49 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BCLI
    $BIOL
    $CDT
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

    – Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – – Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors – – Cash runway expected to extend into 2028 – SAN JOSE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third

    11/6/25 4:30:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

    King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to his new role as Lead Independent Director. He was with JP Morgan for over 27 years, both in M&A and leading the Health Group in investment banking for his last 12 years there. Mr. Deming was appointed

    10/31/25 10:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BCLI
    $BIOL
    $CDT
    Financials

    Live finance-specific insights

    View All

    CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures

    2/20/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are making steady progress toward stabilizing our financial situation and initiating our Phase 3b study of NurOwn, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, President and CEO. "We have been working closely with our network of clinical sites and with our selected manufacturing partners to ensure operational readiness. We also continue to engage with

    11/14/25 4:30:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

         Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new licensing agreement TARPON SPRINGS, Fla., November 14, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the third quarter ended September 30, 2025. "The third quarter of 2025 was another milestone period for Allarity as we ac

    11/14/25 9:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BCLI
    $BIOL
    $CDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OptiNose Inc.

    SC 13G - OptiNose, Inc. (0001494650) (Subject)

    11/20/24 5:21:26 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 7:14:21 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

    SC 13G/A - OptiNose, Inc. (0001494650) (Subject)

    11/14/24 4:54:20 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care